Cleave adds $10m to Series A for cancer drugs
This article was originally published in Scrip
Cleave Biosciences has added $10 million to the $44 million Series A round that the Burlingame, California-based company raised in 2011 to move its first lead oncology compound into the clinic this year and advance a second cancer drug discovery program.
You may also be interested in...
Cleave Biosciences leads off a recent slate of venture capital financings with $37m to fund ongoing Phase I programs for the lead drug from its protein homeostasis-focused platform.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.